10 Hottest Large-Cap Stocks of 2025

Page 9 of 9

1. ABIVAX Société Anonyme (NASDAQ:ABVX)

Market Capitalization as of December 29: $10.99 billion

Number of Hedge Fund Holders: 56

Year-to-Date Performance as of December 29: 1826.02%

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the hottest large-cap stocks of 2025. On December 16, Piper Sandler raised the firm’s price target on Abivax to $142 from $112, while maintaining an Overweight rating on the shares.

On the same day, Citizens raised the firm’s price target on ABIVAX Société Anonyme (NASDAQ:ABVX) to $131 from $114, while keeping an Outperform rating on the shares. The firm highlighted that Abivax’s Q3 2025 results and operational milestones, specifically noting that the Phase 3 ulcerative colitis data released in August, reinforce the drug’s potential to redefine standard clinical care.

A day before, on December 15, Abivax reported cash and cash equivalents of €589.7 million, a substantial increase from the €144.2 million held at the end of 2024. This liquidity surge was primarily driven by a massive public offering completed on July 28, which generated ~$700.3 million (€597.2 million) in net proceeds. Consequently, Abivax has extended its projected cash runway into the fourth quarter of 2027.

The company’s net loss for the first nine months of 2025 widened to €254.1 million, compared to €136.9 million during the same period in 2024. This was largely due to an increase in R&D expenses, which rose by €25.4 million to reach €133.4 million. These costs were driven by the progression of the ABTECT Phase 3 trials for obefazimod in ulcerative colitis and Phase 2b trials for Crohn’s disease. Additionally, the company saw a spike in personnel-related expenses, specifically a €14.8 million increase in employer contributions, triggered by a significant rise in the company’s share price during Q3 2025.

ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company that develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

While we acknowledge the potential of ABVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABVX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9